Leaps by Bayer and Redmile lead GRO Biosciences funding

Emerging biotech GRO Biosciences (GRObio), which is leveraging ground-breaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the closing of a Series A financing totaling $25 million co-led by Leaps by Bayer and Redmile Group.

The financing was joined by lead seed investors Digitalis Ventures, Innovation Endeavors and others bringing the total investment to $31.2 million.

GRObio’s mission is to transform protein-based therapies for increasingly prevalent chronic medical conditions including autoimmune and metabolic diseases. Protein therapeutics represent a nearly $200 billion market, yet product stability, immunogenicity, and delivery into the cell remain significant obstacles to treatment. GRObio is identifying, addressing, and removing these and other limitations to provide safer, simpler, and more effective therapies that improve the lives of patients. The capital raised will support development of the GRO platform, scale-up of bioprocess manufacturing, pre-clinical validation studies and IND-enabling studies for GRObio’s pipeline of unique non-standard amino acid (NSAA) protein therapeutics to treat autoimmune and metabolic diseases.